COR Therapeutics, Inc. Scheduled For FDA Advisory Panel Review of Integrilin (Antithrombotic Injection).SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jan. 15, 1997-- COR Therapeutics, Inc. (Nasdaq: CORR CORR Used on the consolidated tape to indicate a correction in a reported transaction : CORR.LAST.GY 50 WAS 51. ) announced today that the U.S. Food and Drug Administration (FDA) has scheduled the INTEGRILIN(TM) product for review at the FDA's Cardiovascular and Renal Drugs Advisory Committee meeting scheduled on February 27 and 28, 1997. The NDA for the INTEGRILIN(TM) product was submitted in April 1996 seeking approval to market INTEGRILIN(TM) for use in helping to prevent acute cardiac ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic complications in patients undergoing percutaneous transluminal coronary angioplasty percutaneous transluminal coronary angioplasty n. Abbr. PTCA A procedure for enlarging a narrowed arterial lumen by peripheral introduction of a balloon-tip catheter followed by dilation of the lumen as the inflated catheter tip is (PTCA PTCA abbr. percutaneous transluminal coronary angioplasty PTCA Percutaneous transluminal coronary angioplasty, see there ). Schering- Plough Corporation is COR's worldwide partner for INTEGRILIN(TM). COR Therapeutics, Inc. is dedicated to the discovery, development and commercialization of novel pharmaceutical products for the treatment and prevention of severe cardiovascular diseases. The INTEGRILIN(TM) product is also being studied for the treatment of unstable angina and acute myocardial infarction acute myocardial infarction (  ·kyōōtˑ mī·ō·karˑ·dē· . COR has complementary product research and development programs that address critical needs in severe cardiovascular care, including unstable angina, acute myocardial infarction, deep vein thrombosis A blood clot (thrombos) in a vein deep within the muscle, typically in the thigh or calf. It is caused by disease or the lack of activity such as sitting for hours at a computer screen. and restenosis. This press release contains forward-looking statements that are subject to risks and uncertainties. A full discussion of the Company's operations and financial condition, including factors that may affect future operating results, is contained in documents the Company files with the SEC, such as Form 10-Q and 10-K reports. These documents identify important factors that could cause the Company's actual performance to differ from current expectations. CONTACT: COR Therapeutics, Inc. Laura A. Brege or Jacquelyn A. Jeffries, 415/244-6893 or Burns McClellan, Inc. Jonathan M. Nugent, 212/505-1919 (IR) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion